Pirfenidone for the treatment of idiopathic pulmonary fibrosis: Therapeutic potential prompts further investigation

Expert Opinion on Investigational Drugs

Volumn 14, Issue 11, 2005, Pages 1443-1447

  Antoniu, Sabina A ^a  

^a Clinic of Pulmonary Disease   (Romania)

Author keywords

Efficacy; IPF; Pirfenidone; Safety

Indexed keywords

ACETYLCYSTEINE; ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; BLEOMYCIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; GAMMA INTERFERON; GAMMA1B INTERFERON; IMMUNOSUPPRESSIVE AGENT; ORPHAN DRUG; PIRFENIDONE; PLACEBO; PREDNISONE;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BRADYCARDIA; CLINICAL STUDY; CLINICAL TRIAL; DISEASE COURSE; DISEASE EXACERBATION; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; EUROPE; FACIAL NERVE PARALYSIS; FEVER; HEADACHE; HUMAN; IDIOPATHIC DISEASE; INTERSTITIAL PNEUMONIA; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LUNG FIBROSIS; NONHUMAN; PATHOGENESIS; PHOTOSENSITIVITY; PRACTICE GUIDELINE; UNITED STATES; VOMITING;

EID: 27744457401     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.11.1443     Document Type: Article

References (18)

1. AMERICAN THORACIC SOCIETY: Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am. J. Respir. Crit. Care Med. (2000) 161(2 Part 1):646-664.
2. THANNICKAL VJ, FLAHERTY KR, MARTINEZ FJ, LYNCH JP III: Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy. Expert Opin. Pharmacother. (2004) 5(8):1671-1686.
3. HALLSTRAND TS, BOITANO LJ, JOHNSON WC et al.: The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis. Eur. Respir. J. (2005) 25(1):96-103.
4. IYER SN, GURUJEYALAKSHMI G, GIRI SN: Effects of pirfenidone on transforming growth factor-β gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Ther. (1999) 291(1):367-373.
5. FLAHERTY KR, TOEWS GB, LYNCH JP III et al.: Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am. J. Med. (2001) 110(4):278-282.
6. RAGHU G, DEPASO WJ, CAIN K et al.: Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am. Rev. Respir. Dis. (1991) 144(2):291-296.
7. ZISMAN DA, LYNCH JP III, TOEWS GB et al.: Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: a prospective study in patients who failed to respond to corticosteroids. Chest (2000) 117(6):1619-1626.
8. 1b in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. (2004) 350(2):125-133.
9. SHAHZEIDI S, SARNSTRAND B, JEFFERY PK, McCANULTY RJ, LAURENT GJ: Oral N-acetylcysteine reduces bleomycin-induced collagen deposition in the lungs of mice. Eur. Respir. J. (1991) 4(7):845-852.
10. DEMEDTS M BEHR J, BUHL R et al: IFIGENIA: effects of N-acetylcysteine (NAC) on primary end points VC and DLco. Eur. Respir. J. (2004) 24(Suppl. 48):668s.
11. DEMEDTS M. BJ, BUHL R et al: IFIGENIA-study in IPF: effects of N-acetylcysteine (NAC) on CRP, dyspnea, exercise test and HRCT. Eur. Respir. J. (2004) 24(Suppl. 48):668s.
12. AZUMA A, NUKIWA T, TSUBOI E et al.: Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. (2005) 171(9):1040-1047.
13. IYER SN, GURUJEYALAKSHMI G, GIRI SN: Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Ther. (1999) 289(1):211-218.
14. MISRA HP, RABIDEAU C: Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals. Mol. Cell. Biochem. (2000) 204(1-2):119-126.
15. NAKAZATO H, OKU H, YAMANE S, TSURUTA Y, SUZUKI R: A novel antifibrotic agent pirfenidone suppresses tumor necrosis factor-α at the translational level. Eur. J. Pharmacol. (2002) 446(1-3):177-185.
16. NAGAI S, HAMADA K, SHIGEMATSU M et al.: Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern. Med. (2002) 41(12):1118-1123.
17. RAGHU G, JOHNSON WC, LOCKHART D, MAGETO Y: Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am. J. Respir. Crit. Care Med. (1999) 159(4 Part 1):1061-1069.
18. KING TE Jr, SAFRIN S, STARKO KM et al.: Analyses of efficacy end points in a controlled trial of interferon-γ for idiopathic pulmonary fibrosis. Chest (2005) 127(1):171-177.